The Win Ratio: Impact of Censoring and Follow-up Time and Use with Nonproportional Hazards
Overview
Public Health
Affiliations
The win ratio has been studied methodologically and applied in data analysis and in designing clinical trials. Researchers have pointed out that the results depend on follow-up time and censoring time, which are sometimes used interchangeably. In this article, we distinguish between follow-up time and censoring time, show theoretically the impact of censoring on the win ratio, and illustrate the impact of follow-up time. We then point out that, if the treatment has long-term benefit from a more important but less frequent endpoint (eg, death), the win ratio can show that benefit by following patients longer, avoiding masking by more frequent but less important outcomes, which occurs in conventional time-to-first-event analyses. For the situation of nonproportional hazards, we demonstrate that the win ratio can be a good alternative to methods such as landmark survival rate, restricted mean survival time, and weighted log-rank tests.
Huang X, Wang J, Ning J Stat Med. 2024; 43(30):5922-5934.
PMID: 39582325 PMC: 11645213. DOI: 10.1002/sim.10282.
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.
Weatherald J, Fleming T, Wilkins M, Cascino T, Psotka M, Zamanian R Eur Respir J. 2024; 64(4).
PMID: 39209468 PMC: 11525337. DOI: 10.1183/13993003.01205-2024.
Defining estimand for the win ratio: Separate the true effect from censoring.
Mao L Clin Trials. 2024; 21(5):584-594.
PMID: 39076157 PMC: 11502278. DOI: 10.1177/17407745241259356.
Win Statistics in Pulmonary Arterial Hypertension Clinical Trials.
Weatherald J, Moutchia J, Al-Naamani N, McClelland R, Ventetuolo C, Palevsky H Am J Respir Crit Care Med. 2023; 208(11):1231-1234.
PMID: 37734029 PMC: 10868347. DOI: 10.1164/rccm.202305-0800LE.
Mao L Stat Biopharm Res. 2023; 15(3):540-548.
PMID: 37663164 PMC: 10473860. DOI: 10.1080/19466315.2022.2110936.